Do You Have to Stay on Wegovy Long-Term?

The core decision: treatment as a long-term tool or a time-limited course?

This is a question our prescribers hear most weeks, and it sits at the heart of how you use this medicine. Wegovy works by activating GLP-1 receptors involved in appetite signalling. While you're taking it, your body receives a continuous signal that changes how hungry you feel and how quickly your stomach empties. Stop the medicine, and those signals revert. The biology driving your appetite before treatment is still there, the medicine hasn't altered it permanently.

Clinical follow-up studies, including data from the STEP programme published in the New England Journal of Medicine, showed that participants who stopped semaglutide after 68 weeks regained most of the weight they had lost within the following year. That isn't a failure of the treatment; it's the expected pharmacology. It does, though, make the question of how long to continue a genuinely important one.

There are two broad positions. Some people use Wegovy as a defined course: to reach a target, build sustainable habits, and then carefully step off with their prescriber's support. Others treat it as an ongoing tool, much as someone with high blood pressure takes medication long-term. Neither approach is wrong in principle. The right one depends on how your body responds, how you tolerate the medicine over time, and what you and your prescriber decide at each review.

What the NICE guidance actually says, and what it doesn't mean for everyone

Under NICE's appraisal of semaglutide (TA875), treatment on the NHS is recommended for a maximum of two years, within a specialist weight management service with multidisciplinary support. That two-year limit is a condition of the NHS commissioning recommendation, not a clinical verdict that the medicine becomes unsafe or ineffective after 24 months.

For people accessing treatment privately, that specific ceiling doesn't apply in the same way. What does apply is ongoing clinical oversight. A prescriber should assess whether you're still responding well, whether side effects are manageable, and whether continuing is appropriate given your overall health picture. On the Wegovy treatment page you'll find more detail on how the medicine is used in the UK and what eligibility looks like. At nume, every repeat order is reviewed by a GPhC-registered prescriber before it's approved, there are no automatic renewals.

If you're also weighing up whether semaglutide or tirzepatide is the better fit for your situation, the semaglutide overview covers how the two medicines compare mechanically. That comparison matters when you're thinking about long-term treatment, because the answer can differ by medication.

Factors that shape the continuing-vs-stopping decision for you specifically

Your prescriber will consider several things at each review. First, are you still losing weight, or have you stabilised at a point that represents a meaningful health benefit? NICE suggests that if fewer than 5% of body weight has been lost after six months at the maintenance dose, it's worth reassessing. That's a guideline for review, not an automatic instruction to stop.

Second, tolerability matters over time. Some people find gastrointestinal side effects (nausea, changes in bowel habit, reflux) settle within the first few weeks and never return. Others find low-level symptoms persist. If side effects are affecting quality of life significantly, a dose reduction or a switch to an alternative is worth discussing before simply stopping. The weight-loss treatments overview sets out the options that exist for adults in the UK.

Third, lifestyle changes matter alongside the medicine, not instead of it. People who use the reduced appetite to build genuinely different eating habits tend to do better after stopping than those who haven't made those changes. Wegovy is licensed alongside a reduced-calorie diet and increased physical activity for a reason. If you're curious about the wider age-related picture, the age requirements for Wegovy page covers who the licence applies to.

Stopping, pausing, or continuing: practical points

If you and your prescriber decide to stop, there's no clinical requirement to taper the dose gradually, unlike some other medicines. You can simply not take the next weekly dose. The effects will wear off over the following weeks as the medicine clears your system. What most people notice is that appetite returns, sometimes noticeably.

Pausing temporarily (for surgery, pregnancy planning, or a period where supply is interrupted) is different from stopping indefinitely. The question of whether Wegovy has to be lifelong is worth reading alongside this page, because long-term continuation and indefinite continuation aren't the same thing. Some people restart after a planned break; the clinical picture is reviewed fresh each time.

There's also a cost dimension to long-term treatment that's worth acknowledging honestly. Private treatment is a recurring expense, and it's reasonable to factor that in. The guide to Wegovy costs in the UK explains what the market looks like and what a legitimate private price typically includes. For a broader view of whether long-term use is right for you, the page on staying on Wegovy for life goes further into the evidence. If you'd like to talk through where you are in your treatment and what makes sense next, speaking to our prescribers is the right starting point, consultations are free, and every review is done by a real clinician, not automated software.